HOOK News and Press, HOOKIPA Pharma Inc. From 08/17/22

The following slide deck was published by HOOKIPA Pharma Inc. in conjunction with this event. For further details see: HOOKIPA Pharma (HOOK) August-2022-Investor-Presentation

HOOKIPA Pharma press release ( NASDAQ: HOOK ): Q2 GAAP EPS of -$0.23 beats by $0.14 . Revenue of $2.75M (-49.1% Y/Y) misses by $0.61M . HOOKIPA’s cash, cash equivalents and restricted cash as of June 30, 2022 was $118.9 million compared to...

HB-200 Phase 1 data presented at ASCO met all endpoints in heavily pre-treated head and neck cancer patients; Phase 2 study underway US Food and Drug Administration accepted HOOKIPA’s Investigational New Drug Application for HB-300 for the treatment of metastatic castr...

NEW YORK and VIENNA, Austria, Aug. 04, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapies based on its proprietary arenavirus platform, today announced that it will release its second quarter 2022 financi...

Clinical-stage biotech HOOKIPA Pharma ( NASDAQ: HOOK ) announced on Monday that the FDA accepted its Investigational New Drug (IND) application for HB-300, an experimental therapy for metastatic castration-resistant prostate cancer. A Phase 1/2 trial for the treatment is expec...

Novel arenaviral immunotherapy is directed against the prostate cancer targets PAP and PSA; Phase 1/2 trial to commence by early 2023 Drug Master File (DMF) accepted to support future FDA submissions NEW YORK and VIENNA, Austria, July 25, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharm...

NEW YORK and VIENNA, Austria, June 21, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced several leadership changes as the company expands...

NEW YORK and VIENNA, Austria, June 09, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the company will participate in investor mee...

Alternating 2-vector therapy showed superior antigen-specific T cell responses, more robust anti-tumor activity and similar tolerability vs. single-vector therapy Phase 2 to proceed with alternating 2-vector therapy in combination with pembrolizumab, which will help inform the ran...

Hookipa Pharma (NASDAQ:HOOK) on Friday announced positive preclinical data from arenaviral therapeutic vaccines that are being studied as a component of a potential functional curative regimen for HIV.  (HOOK) up ~2% before the bell. The studies are being done in coll...